The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient [2]

International Journal of Laboratory Hematology

Volumn 29, Issue 1, 2007, Pages 71-72

  Zhang, S J ^a   Li, J Y ^a   Li, W D ^a   Song, J H ^a   Xu, W ^a   Qiu, H X ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; JANUS KINASE 2; ABELSON KINASE; HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LETTER; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYCYTHEMIA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; THROMBOCYTHEMIA; ADULT; BLOOD SAMPLING; CHINESE; DNA ISOLATION; FEMALE; GENE IDENTIFICATION; MALE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOCYTE COUNT;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; HUMANS; JANUS KINASE 2; MALE; MUTATION, MISSENSE; POINT MUTATION; POLYCYTHEMIA VERA;

EID: 33846135053     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00864.x     Document Type: Letter

References (6)

1. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N. & Green A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061.
2. Campbell P.J. & Green A.R. (2005) Management of polycythemia vera and essential thrombocythemia. Hematology American Society of Hematology. Education Program, 201-208.
3. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N. & Vainchenker W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148.
4. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M. & Skoda R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 352, 1779-1790.
5. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J. & Gilliland D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397.
6. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B. & Zhao Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry 280, 22788-22792.